Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Expands By 52.4%

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 3,520,000 shares, an increase of 52.4% from the June 30th total of 2,310,000 shares. Currently, 7.4% of the shares of the stock are short sold. Based on an average trading volume of 578,900 shares, the short-interest ratio is currently 6.1 days.

Institutional Investors Weigh In On Pyxis Oncology

Several large investors have recently modified their holdings of the company. Fullcircle Wealth LLC acquired a new position in Pyxis Oncology in the second quarter valued at $40,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology during the 1st quarter valued at about $59,000. Cetera Advisors LLC bought a new stake in shares of Pyxis Oncology during the 1st quarter valued at about $100,000. Cable Car Capital LLC acquired a new stake in Pyxis Oncology during the fourth quarter worth approximately $111,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Pyxis Oncology in the first quarter valued at approximately $351,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $10.00 price target on shares of Pyxis Oncology in a report on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, May 16th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $8.80.

Pyxis Oncology Stock Performance

Shares of PYXS traded down $0.05 during mid-day trading on Monday, reaching $3.83. 462,622 shares of the company were exchanged, compared to its average volume of 696,565. The business has a 50 day simple moving average of $3.49 and a two-hundred day simple moving average of $4.17. The stock has a market capitalization of $225.55 million, a PE ratio of -2.82 and a beta of 1.28. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Saturday, May 11th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to analyst estimates of $4.25 million. On average, analysts predict that Pyxis Oncology will post -1.09 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.